Navigation Links
Essentialis Promotes Aaron Berg to Chief Executive Officer
Date:12/7/2011

SAN DIEGO, Dec. 7, 2011 /PRNewswire/ -- Essentialis, Inc., announced today the promotion of Aaron D. Berg from President and Chief Commercial Officer to Chief Executive Officer (CEO).  Essentialis is focused on the development of a novel medicine for the treatment of cardiovascular and metabolic disease.  Mr. Berg joined Essentialis in January, 2010 bringing proven business development and product commercialization expertise to the Company and its lead compound, DCCR, now in Phase II development for patients with very high triglycerides.  Mr. Berg was also appointed to the Essentialis Board of Directors.

"Aaron Berg has brought to Essentialis expertise and knowledge from senior positions at Schering-Plough and Kos Pharmaceuticals," said Stuart Collinson, Ph.D., Chairman of the Board.  "As we now transition from mid-stage development to the next phase in our evolution, the Board of Directors recognized Aaron's cardiovascular and metabolic disease expertise make him an ideal leader for Essentialis."

About Aaron Berg

With more than 25 years of industry experience, Mr. Berg demonstrated a consistent record of advancement from sales representative to the pharma c-suite. After beginning his pharmaceutical industry career with Bristol-Myers Squibb, Mr. Berg spent 10 years with Schering-Plough, where he worked in numerous positions of increasing responsibility throughout the commercial organization. Mr. Berg was next recruited by GlaxoSmithKline to help build its newly launched diabetes franchise and then sought an entrepreneurial path.

In 2001, he joined then early stage Kos Pharmaceuticals as a marketing director and rose to Vice President, Marketing and Sales. Kos became widely viewed as a tremendous industry success story, and was acquired by Abbott Laboratories in December, 2006 for $3.6 billion.  His commercial expertise in lipid therapy and understanding of the compound DCCR led Essentialis to tap Mr. Berg as president and now CEO.

About DCCR

DCCR, is a proprietary crystalline salt of diazoxide in a controlled-release, once-a-day tablet formulation. It is in development for patients with very high triglycerides. Essentialis expects to initiate Phase 3 clinical trials in 2012.  DCCR is covered by multiple issued US patents, which provide composition of matter protection until 2028.  Essentialis has evaluated DCCR in several double-blind, placebo-controlled studies which demonstrated that the drug was well tolerated and statistical significance for various endpoints was achieved in patients with elevated triglycerides. More than 100,000 patient-years of treatment with diazoxide help support the acceptable safety of DCCR.

About Essentialis, Inc.

Essentialis is a San Diego-headquartered pharmaceutical company focused on the development of breakthrough medicines targeted to the ATP-sensitive potassium channel, a metabolically regulated membrane protein whose modulation has potential to treat and prevent a wide range of cardiovascular and metabolic diseases.  For more information visit http://essentialistherapeutics.com/

Contacts:

Kristie Kuhl
kkuhl@makovsky.com
212-508-9642

Or

Aaron Berg
aberg@essentialistherapeutics.com
858-964-5022

 


'/>"/>
SOURCE Essentialis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio
2. Essentialis to Submit SPA for Hypertriglyceridemia
3. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
4. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
5. Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer
6. Par Pharmaceutical Companies Promotes Thomas J. Haughey to President and Paul V. Campanelli to Chief Operating Officer
7. Prescription-Drug Plans Use of Specialty Tiers Promotes Inequalities
8. InspireMD Promotes MGuard™ at the EuroPCR 2011 Exhibition and Conference in Paris This Week
9. More Dangerous Than Drunk Driving, Hope Paige Designs Promotes a THUMBAND for Safe Texting
10. American Imaging Management Promotes Affordability and Choice to Health Care Consumers
11. Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):